Coronavirus: drug gives hope
New research from the UK to make hope in the fight against the Coronavirus SARS-CoV-2 and the pathogen-triggered disease COVID-19. A drug to be Inhaled can gradients, therefore, the risk for severe disease, as well as the risk of death dramatically reduce.
In a recent communication, the University of Southampton and the drug development company Synairgen positive results from clinical studies with the drug SNG001 (an inhaled formulation of Interferon beta) reports. The treatment with the inhaled drug could prevent deterioration of COVID-19 in the case of the most vulnerable people.
No Deaths
The probability that it comes during the treatment period (day 1 to day 16) to a severe course of the disease (of power, for example, a ventilation or death), was received in the case of Sufferers, the SNG001, in comparison to those given a Placebo, a significant 79 percent reduction.
In addition, the probability of a recovery was received is defined (as “no restriction of activities” or “there is no clinical or virological evidence of infection”) in the course of the treatment period, in patients, the SNG001, more than twice as high as in those treated with a Placebo.
In addition, the extent of the COVID-19 caused shortness of breath in Patients receiving SNG001 was reduced, in comparison to those given a Placebo, significantly. Three subjects (six percent) died after randomization in the Placebo group. In the case of persons who have been treated with SNG001, there were no deaths.
Significantly better healing chances
In the placebo-controlled double-blind study of 30. March to 27. In may 2020, a total of 101 Corona Patients from nine hospital sites in the UK included. They had an average age of 56.5, respectively, of 57.8 years (placebo group) and showed an average of 9.8 days sickness symptoms.
In the case of the persons who were ill at the time of the recording is difficult (i.e., those that required treatment with supplemental oxygen) increased the SNG001 treatment, the probability of a discharge from the hospital during the study, but the difference was not statistically significant. The median time to discharge was six days for the treated with SNG001, and nine days for the Participants who received a Placebo.
In addition, it seemed to those who SNG001 got to be more than twice as likely to be that they had recovered at the end of the treatment period, although this strong Trend did not achieve statistical significance. 28. Day patients and patients receiving SNG001 treatment had chances, statistically significantly better healing.
Interestingly, the analyses show that there is no indication of a connection between the positive treatment effects of SNG001 and the previous duration of the COVID-19 symptoms.
In the coming weeks, further analysis is to be carried out.
Shortness of breath significantly reduced
“The results confirm our Belief that Interferon beta, a widely known drug that was approved for use in a number of other indications by injection, has a great potential as an inhaled medication to the immune response of the lung to re-establish and improve the protection, to speed up the recovery and the impact of the SARS-CoV-2-Virus counter”, said Professor Tom Wilkinson, Professor of respiratory medicine at the University of Southampton.
“We are all pleased with today’s announced study results, which show that SNG001 reduces the number of COVID-19-hospital patients who could switch from “oxygen need” to “breathing subject”, strong. They also showed that patients receiving SNG001, recover with at least twice as high probability so that their daily activities were not affected by a SARS-CoV-2 infection,“ says Richard Marsden, CEO of Synairgen.
“In addition, SNG001 has reduced shortness of breath, one of the main symptoms of severe COVID-19, significantly. This review of SNG001 in COVID-19-patients could mean a major breakthrough in the treatment of hospitalized COVID-19-patients. Our efforts are focused now, with the Supervisory authorities and other key groups to work together, this potential COVID-19-advance the treatment as quickly as possible.“ (ad)